Literature DB >> 12783216

Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.

Nitya G Chakraborty1, Robert L Stevens, Shikhar Mehrotra, Elizabeth Laska, Pamela Taxel, Jonathan R Sporn, Peter Schauer, Peter C Albertsen.   

Abstract

Prostate-specific antigen (PSA) is a valuable marker antigen for prostate cancer. Lately considerable interest has been generated in the prospect of developing a vaccine for prostate cancer with PSA-derived peptide epitopes to induce cytotoxic T-cell (CTL) response. We report here that T cells capable of exhibiting PSA epitope-specific effector function-in their native state, i.e, without having to be further stimulated, in vitro-are detectable in more than half of the prostate cancer patients we studied. Ex vivo cultured autologous dendritic cells (DC) were used to present four HLA-A2-binding PSA peptide epitopes to freshly isolated peripheral blood lymphocytes (PBL) from patients and healthy volunteers. Ten out of 14 patients' PBL recognized at least one of the four peptides and 6 out of 10 patients' PBL recognized more than one peptide antigen as measured by IFN-gamma secretion upon stimulation of the PBL with the peptide antigen. Intracytoplasmic cytokine analysis for IFN-gamma in purified CD8(+) cells after stimulation with peptide antigens was tested in 6 patients and this technique demonstrated a similar response. Freshly isolated and purified CD8(+) cells when tested, also recognized the epitopes, as measured by IFN assay, when presented by transporter associated with antigen-processing (TAP) deficient T2 cells in an MHC-I restricted fashion. PBL from 9 normal donors when tested in identical fashion did not show any IFN-gamma production in recognition to the peptide antigens. Interestingly, neither of these CD8(+) T cells having IFN-gamma-producing ability did show any cytolytic activity in their native state against peptide loaded target cells or tumor cells when tested in cytotoxicity assay. In long term cocultures stimulation of purified CD8(+) T cells with matured DC pulsed with PSA peptides generated a PSA-specific CTL response in 4 of 6 patients studied and in 2 of 9 normal donors. While our observations of CTL generation are consistent with the prior reports that have demonstrated that specific CD8(+) CTL could be generated which recognize PSA-derived epitopes by in vitro stimulation by one means or another, this observation that IFN-gamma-producing CD8(+) T cells are present in patients which are antigen experienced, and do not require in vitro stimulation, is novel and has major implications for prostate cancer vaccine preparation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12783216     DOI: 10.1007/s00262-003-0377-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  14 in total

1.  Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated Immunosenescence.

Authors:  Jeffrey N Dock; Rita B Effros
Journal:  Aging Dis       Date:  2011-10       Impact factor: 6.745

2.  In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.

Authors:  Elizabeth J Akins; Miranda L Moore; Shuai Tang; Mark C Willingham; Janet A Tooze; Purnima Dubey
Journal:  Cancer Res       Date:  2010-04-20       Impact factor: 12.701

Review 3.  Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.

Authors:  Ravi A Madan; James L Gulley
Journal:  Expert Rev Vaccines       Date:  2011-02       Impact factor: 5.217

Review 4.  Landscape of Immunotherapy in Genitourinary Malignancies.

Authors:  Deepak Ravindranathan; Omar Alhalabi; Hind Rafei; Amishi Yogesh Shah; Mehmet Asim Bilen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  T cell replicative senescence in human aging.

Authors:  Jennifer P Chou; Rita B Effros
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

7.  Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.

Authors:  Ravi A Madan; James L Gulley; Philip W Kantoff
Journal:  Cancer J       Date:  2013 Jan-Feb       Impact factor: 3.360

8.  Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer.

Authors:  Barbara Seliger; Robert Stoehr; Diana Handke; Anja Mueller; Soldano Ferrone; Bernd Wullich; Andrea Tannapfel; Ferdinand Hofstaedter; Arndt Hartmann
Journal:  Cancer Immunol Immunother       Date:  2009-10-07       Impact factor: 6.968

Review 9.  Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Authors:  Ravi A Madan; Philip M Arlen; Mahsa Mohebtash; James W Hodge; James L Gulley
Journal:  Expert Opin Investig Drugs       Date:  2009-07       Impact factor: 6.206

10.  A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy.

Authors:  Tracy R Daniels-Wells; Gustavo Helguera; Richard K Leuchter; Rafaela Quintero; Maggie Kozman; José A Rodríguez; Elizabeth Ortiz-Sánchez; Otoniel Martínez-Maza; Birgit C Schultes; Christopher F Nicodemus; Manuel L Penichet
Journal:  BMC Cancer       Date:  2013-04-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.